Shows
MarketVibe - S&P 500 Business Analysis | Business InvestingAbbVie: The House That Humira BuiltExplore how AbbVie used a single blockbuster drug to fund a $63 billion transformation and master the art of the 'patent thicket.'[INTRO]ALEX: Imagine you owned a single product that made twenty billion dollars in a single year. Just one drug, accounting for over sixty percent of your entire company's value.JORDAN: That sounds like a dream. Why am I sensing a 'but' coming?ALEX: Because that one drug, Humira, was heading toward a 'patent cliff'—a date where the monopoly ends and the money vanishes. Today we’re looking at A...
2026-02-2304 min
Beta Finch - S&P 100 - FRAbbVie Q4 2025 Earnings Analysis**Beta Finch - Episode: AbbVie Q4 2025**ALEX: Bienvenue à Beta Finch, votre analyse d'earnings générée par IA ! Je suis Alex, et avec moi aujourd'hui Jordan pour décortiquer les résultats du quatrième trimestre 2025 d'AbbVie. Ce podcast est un contenu généré par intelligence artificielle à des fins éducatives et de divertissement uniquement. Rien de ce que nous discutons ne doit être considéré comme un conseil en investissement. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.JORDAN: Salut Alex ! Alors, AbbVie a vraiment frappé f...
2026-02-2207 min
Beta Finch - S&P 100 - ESAbbVie Q4 2025 Earnings Analysis**ALEX:** ¡Bienvenidos a Beta Finch, su análisis de resultados financieros impulsado por inteligencia artificial! Soy Alex, y me acompaña mi co-anfitrión Jordan. Hoy desglosamos los resultados del cuarto trimestre de 2025 de AbbVie, que acaba de reportar números verdaderamente impresionantes.Antes de comenzar, quiero aclarar algo importante: Este podcast es contenido generado por inteligencia artificial solo con fines educativos y de entretenimiento. Nada de lo que discutimos debe considerarse asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero calificado antes de tomar decisiones de inversión.**JORDAN...
2026-02-2210 min
Beta Finch - S&P 100 - ENAbbVie Q4 2025 Earnings Analysis**Beta Finch Podcast Script: AbbVie Q4 2025 Earnings**---ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex.JORDAN: And I'm Jordan. Today we're diving into AbbVie's fourth quarter 2025 results, and wow, what a story this pharmaceutical giant has to tell.ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified...
2026-02-2208 min
Beta Finch - S&P 100 - DEAbbVie Q4 2025 Earnings Analysis**Beta Finch Podcast Script - AbbVie Q4 2025 Earnings**ALEX: Willkommen zu Beta Finch, Ihrer KI-gestützten Ergebnisanalyse! Ich bin Alex.JORDAN: Und ich bin Jordan. Heute schauen wir uns AbbVies beeindruckende Q4 2025-Ergebnisse an.ALEX: Bevor wir beginnen, ein wichtiger Hinweis: Dieser Podcast ist ein von künstlicher Intelligenz generierter Inhalt, der nur zu Bildungs- und Unterhaltungszwecken dient. Nichts von dem, was wir besprechen, sollte als Anlageberatung betrachtet werden. Recherchieren Sie immer selbst und konsultieren Sie einen qualifizierten Finanzberater, bevor Sie Anlageentscheidungen treffen.JORDAN: Absolut richtig, Alex. Also, was für ein Jah...
2026-02-2208 min
Project E | Dein Earnings-PodcastAbbVie Earnings Q4 2025 | Rekordumsätze, Pipeline-Expansion und der 100-Milliarden-Dollar-DealIn dieser Episode beleuchten wir die starken Finanzergebnisse von AbbVie für das vierte Quartal und das Gesamtjahr 2025, in dem das Unternehmen einen Umsatzanstieg auf über 61 Milliarden US-Dollar verzeichnete. Wir analysieren, wie die Wachstumstreiber Skyrizi und Rinvoq den Umsatzrückgang von Humira erfolgreich kompensierten und welche Rolle das Neurologie-Portfolio spielt. Zudem diskutieren wir die neuesten Entwicklungen in der R&D-Pipeline, darunter Zulassungsanträge für Rinvoq bei Vitiligo und neue Krebsimmuntherapien, sowie die historische Vereinbarung mit der US-Regierung über Investitionen von 100 Milliarden US-Dollar. Ein Ausblick auf die positive Gewinnprognose für 2026 rundet die Analyse ab.Quelle: https://investo...
2026-02-0513 min
Rapid Money RadioAbbVie’s 460% Patent Win; Merck, BMY Next 01/23/26AbbVie’s 460% Patent Win; Merck, BMY Next 01/23/26
Key Stories:
AbbVie, the pharmaceutical giant, saw its shares surge an incredible 460% after successfully extending the patent life on its blockbuster drug, Humira. This strategic move allowed AbbVie to mitigate what could have been a significant revenue “patent cliff”—a steep drop in sales once a drug’s patent expires and generic or biosimilar versions enter the market. The company used this extended period to develop new revenue streams, more than replacing Humira’s sales before its exclusivity eventually ended. This successful navigation now places a spotlight on other major pharma...
2026-01-2300 minRapid Money RadioAbbVie’s 30% Rally, AI Picks Under $50 01/03/26AbbVie’s 30% Rally, AI Picks Under $50 01/03/26
Key Stories:
AbbVie, the pharmaceutical giant, has delivered a truly impressive year-to-date outperformance, with its shares climbing nearly 30%. This significant rally has been met with robust optimism from analysts. However, despite the strong upward momentum and positive sentiment, market watchers are generally maintaining a ‘Hold’ rating on the stock, suggesting that while the performance is convincing, the current valuation may not offer a compelling entry point for new investors. It’s a classic case of strong performance versus a potentially stretched price tag, leaving investors to weigh the growth against current...
2026-01-0400 min
Daily Market DownloadAbbVie 2025 Third Quarter Form 10-Q ReportThe provided documents offer an overview of AbbVie's financial performance and strategic activities for the third quarter of 2025. The first source contains excerpts from the Third Quarter 2025 Earnings Conference Call, featuring commentary from executives like CEO Rob Michael and CCO Jeff Stewart, highlighting strong financial results, a raised 2025 outlook, and the continued success of key immunology drugs SKYRIZI and RINVOQ, despite the anticipated decline in HUMIRA sales due to biosimilar competition. The second source is AbbVie's Form 10-Q Quarterly Report for the period ended September 30, 2025, which includes detailed condensed consolidated financial statements showing net revenues of $15.8 billion...
2025-11-0518 min
The AI in Business PodcastFrom Tool Sprawl to Defensible Value in AI for Legal - with Christo Siebrits of AbbVieToday's guest is Christo Siebrits, Senior Associate and General Counsel at AbbVie. With over 20 years of experience in global pharmaceutical legal and compliance leadership, Siebrits leads AbbVie's AI initiatives and provides strategic guidance on AI-related legal and regulatory matters. Christo joins Emerj Editorial Director Matthew DeMello to discuss how enterprise legal teams can adopt generative AI safely, balance internal versus external data use, and implement human-in-the-loop workflows to manage risk. Siebrits also shares practical strategies for matter-centric processes, measuring AI-driven efficiencies, and making informed decisions on AI investments across internal and external legal operations. We'd like to note for...
2025-10-1327 min
Breaking News To Trading MovesAbbVie IPR&D Charge and Pharmaceutical Sector ImplicationsAbbVie’s $2.7B IPR&D charge hits Q3 and full-year EPS guidance; Street recalibrates expectations. Reuters reports ABBV now sees FY25 adjusted EPS at $10.38–$10.58 (prior $11.88–$12.08) and prelim Q3 EPS at $1.74–$1.78, both below consensus. The charge stems from acquired in-process R&D tied to deals/licensing. This signals continued external pipeline spending even as Humira wanes and newer drugs scale. SummaryAbbVie is prioritizing pipeline building via deals, taking a large non-cash IPR&D expense in Q3 that lowers near-term EPS but implies sustained outsourcing and partnered development activity across immunology, oncology, and neuroscience.
2025-10-0418 min
C éliminéCongrès de l’APSEP : et toi, tu dépistes comment en prison ?Le dépistage en prison représente une opportunité majeure pour identifier des patients souvent éloignés du système de soins classique. Dans cet épisode de C éliminé enregistré lors du congrès de l’Association des Professionnels de Santé Exerçant en Prison (APSEP), nous explorons les enjeux du dépistage de l'hépatite C en milieu pénitentiaire. Les professionnels de santé qui ont témoigné à notre micro partagent leurs pratiques et les stratégies mises en place pour prendre en charge les détenus depuis leur entrée jusqu’à leur sortie de pris...
2025-09-1909 min
VOCES AbbVieMigraña: bulos y leyendasEn este primer episodio de VOCES en migraña, desmontamos los mitos más comunes sobre esta enfermedad de la mano de Maurizio Gentile, Gerente Médico en Neurociencias de AbbVie. En España, se estima que hay más de cinco millones de personas con migraña, una enfermedad neurológica caracterizada por un intenso dolor de cabeza que impacta profundamente en la calidad de vida de quienes la padecen.
Por ello, además de aclarar las falsas creencias en torno a esta enfermedad, descubrimos información clave para comprender mejor qué es la migraña y qué medida...
2025-09-0906 minVOCES AbbVieMigraña: bulos y leyendasEn este primer episodio de VOCES en migraña, desmontamos los mitos más comunes sobre esta enfermedad de la mano de Maurizio Gentile, Gerente Médico en Neurociencias de AbbVie. En España, se estima que hay más de cinco millones de personas con migraña, una enfermedad neurológica caracterizada por un intenso dolor de cabeza que impacta profundamente en la calidad de vida de quienes la padecen.
Por ello, además de aclarar las falsas creencias en torno a esta enfermedad, descubrimos información clave para comprender mejor qué es la migraña y qué medida...
2025-09-0906 min
Pharma and BioTech DailyPharma and Biotech Daily: AbbVie Acquires Gilgamesh, IPO Stalemate Ends, Oral Obesity Therapies DisappointGood morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA...
2025-08-2601 min
Illinois State News and Info TrackerIllinois Unveils Major Economic and Educational Developments with $195M AbbVie Expansion and School Safety InnovationsIllinois listeners are starting the week with several notable headlines. The expansion of the North Chicago AbbVie manufacturing campus stands out as a major business development, with a $195 million project that will create 50 new jobs and bolster local production of critical pharmaceutical ingredients. State officials note this aligns with Illinois’ commitment to supporting innovation and workforce growth in the sciences and manufacturing sectors. On the political front, Governor JB Pritzker continues his review of legislation from the spring session. He has recently signed bills that include reforms to transportation safety, retirement policy for public safety workers, a health insurance special en...
2025-08-1703 min
Know What You Are InvestingAbbVie Q2 2025: Immunology Power & Strategic Pipeline MovesIn this episode of Know What You Are Investing, we unpack AbbVie’s stellar second quarter of 2025. With total revenues surpassing $15.4B and strong performance in immunology, neuroscience, and oncology, AbbVie is showing investors a powerful vision beyond HUMIRA.🔥 What’s Inside🔹 Skyrizi and Rinvoq set to exceed $25B in 2025 combined sales🔹 Neuroscience growth led by Vraylar, QULIPTA, and VYALEV🔹 Oncology resilience and aesthetic segment headwinds🔹 30+ business development deals including obesity, CAR-T, ADCs🔹 Strategic investments in U.S. manufacturing & next-gen therapies🔹 IRA updates and tariff outlook
2025-08-0227 minDaily Market DownloadAbbVie's Q2 2025 Financial PerformanceThis press release details AbbVie's financial performance for the second quarter of 2025, highlighting increased net revenues of $15.423 billion and an adjusted diluted EPS of $2.97. The report provides a breakdown of revenues across key portfolios, including strong growth in Immunology and Neuroscience, while Aesthetics saw a decrease. It also outlines recent product approvals and clinical trial results for drugs like Rinvoq and Emrelis, as well as strategic collaborations and acquisitions aimed at expanding AbbVie's pipeline. Finally, the company raised its full-year 2025 adjusted diluted EPS guidance, reflecting confidence in its continued momentum.
2025-08-0114 min
Future of HR“Unlocking the Power of Employee Experience” with Assil Omar, VP, People Experience, AbbVieHow do you unlock the power of employee experience?Why is a people-first mindset so critical in modernizing HR?My guest on this episode is Assil Omar, VP, People Experience, AbbVie.During our conversation Assil and I discuss:Why we should embrace new opportunities as a way to reinvent ourselves and our careers.How AbbVie maintains a unique culture of purpose, performance, and careWhy HR practitioners must become students of both human motivation and organizational transformation to drive real impact.Why it’s important to start wi...
2025-07-2935 min
EMJ GOLD: Pharma news, views and analysisS10 E08: AbbVie's Dr Daejin Adiboye on community and compassion in cancer careTune in as Dr Daejin Adiboye, Vice President, Therapeutic Area Head, Solid Tumor Oncology, AbbVie, explores both the evolution of cancer care and his leadership style over the last two decades. Together, Daejin and Jade discuss the lessons from his time in the clinic that shaped who he is today, the move to precision medicine in oncology, his work with the Cancer Support Community in San Francisco and much more. A little more on EMJ GOLD's guest… Dr Daejin Abidoye serves as Vice President, Therapeutic Area Head for Solid Tumor Oncology at AbbVie. In...
2025-07-2227 min
Learning Leader Spotlight: Interviews with corporate L&D leadersBuilding Personalized Learning Journeys for Career Growth with Kim Troxell of AbbVieKim Troxell, Head of Commercial Learning and Development of AbbVie, shares how nearly three decades of experience across commercial, international and leadership roles has shaped her approach to driving impact through L&D. Drawing on her time leading teams in Ireland and Denmark and her passion for developing talent, Kim outlines how personalization, microlearning and AI are shaping the future of learning. She also reflects on the value of mentorship and inclusive leadership for long-term growth.Key Takeaways:(02:11) Cross-functional experience can strengthen leadership in L&D.(05:39) Personalization...
2025-07-1524 min
The Top LineAbbVie, ADCs and the future of cancer careAntibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has embraced the trend head-on. In this week’s episode of "The Top Line," Fierce Pharma’s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie’s vice president and therapeutic area head for solid tumor oncology. They discuss the company’s evolution, trends from this year’s American Society of Clinical Oncology meeting and what’s ahead for ADCs in oncology. AbbVie, a newer player in the ADC space...
2025-06-2017 min
VOCES AbbVieSer tu mejor versiónEn este episodio de Voces de AbbVie, Nacho Andrés conversa con Elisa Almansa, Infield Team Coordinator de Oncología, sobre cómo ha construido su trayectoria profesional en la compañía a lo largo de 27 años. En esta nueva entrega, Elisa nos habla su experiencia, de su espíritu de superación y de sus fuentes de inspiración para desarrollar su mejor versión. Una conversación sobre actitud, aprendizaje continuo y desarrollo en AbbVie.
2025-06-0212 minVOCES AbbVieSer tu mejor versiónEn este episodio de Voces de AbbVie, Nacho Andrés conversa con Elisa Almansa, Infield Team Coordinator de Oncología, sobre cómo ha construido su trayectoria profesional en la compañía a lo largo de 27 años. En esta nueva entrega, Elisa nos habla su experiencia, de su espíritu de superación y de sus fuentes de inspiración para desarrollar su mejor versión. Una conversación sobre actitud, aprendizaje continuo y desarrollo en AbbVie.
2025-06-0212 min
Entrevistas CorresponsablesYolanda García (AbbVie): “La diversidad impulsa la innovación: sin ella, no hay avance posible”AbbVie ha sido reconocida con el Distintivo de Igualdad en la Empresa, un galardón que no solo acredita su compromiso con la equidad entre mujeres y hombres, sino que consolida su liderazgo en la construcción de entornos laborales inclusivos. Para Yolanda García, Directora de Recursos Humanos, este distintivo “valida que estamos haciendo las cosas bien” y supone un estímulo colectivo para seguir avanzando con paso firme hacia una cultura cada vez más justa y respetuosa.
En esta conversación, la directiva destaca algunos de los hitos clave en este camino, como la implementación de políticas d...
2025-05-2715 min
Outcomes RocketRedefining Clinical Trials: Sasha Tyndale on Inclusive Research at AbbVieDiseases don't discriminate, so it is crucial that medicines are accessible to and effective for as many people as possible.
In this episode, Sasha Tyndale, Director of Diversity and Patient Inclusion at AbbVie, discusses the company’s commitment to inclusive clinical research, highlighting the importance of representing diverse populations affected by diseases. Sasha shares how her team integrates patient perspectives into clinical program design to proactively address potential barriers. She introduces the ADMIRE program, which is focused on engaging underrepresented healthcare professionals in research. Sasha also emphasizes humanizing the healthcare experience by hearing patient stories and addressing cha...
2025-05-0217 min
Know What You Are Investing🎙️ AbbVie Q1 2025 Earnings – Immunology Momentum, Raised Guidance, and Strategic Growth Moves🎙️ AbbVie Q1 2025 Earnings – Immunology Momentum, Raised Guidance, and Strategic Growth Moves📅 Earning Release: April 25, 2025📄 Sources: AbbVie Q1 2025 Earnings Release, Investor Charts, and Call TranscriptIn this episode, we break down AbbVie’s strong Q1 2025 results, pipeline updates, and future growth strategy beyond Humira.📈 Quarterly Highlights• Revenue: $13.3B (+8.4% YoY reported, +9.8% operational)• Adjusted EPS: $2.46 (+6.5% YoY), beating guidance midpoint• Raised full-year 2025 guidance: EPS now $12.09–$12.29, revenue forecast up $700M to ~$59.7B💊 Portfolio Performance• Immunology: Skyrizi (+70.5% YoY) and Rinvoq (+57.2% YoY) delivered combined $5.1B sales, offsetting Humira’s -50.6% decline• Neuroscience: Strong growth from Vraylar, Botox Therapeutic, and migraine portfolio (Ubrelvy, Qulipta)• Oncology: Solid contributions from Venclexta and Elahere despite Imbruvi...
2025-04-2914 minC éliminéDr François Villeret : et toi, tu dépistes comment en oncologie ?Atteindre l’objectif d’élimination de l’hépatite C d’ici 2030 demande de dépister et traiter les patients porteurs du virus. Mais comment trouver ceux que l’on ne voit pas dans les centres d’accueil ou qui ne consultent pas d’hépatologue ? À Lyon, le Dr François Villeret a pris le problème à bras-le-corps en sensibilisant ses collègues non-hépatologues, notamment en oncologie, en rhumatologie et en psychiatrie. Un exemple des résultats obtenus ? Dans le service d’oncologie de l’Hôpital de la Croix-Rousse, le dépistage fait partie du protocole de pri...
2025-04-2308 min
PETRI DISH PERSPECTIVESEpisode 3: AbbVieSend us a textIn this episode of Petri Dish Perspectives: Biotech Unleashed, we explore the rise of AbbVie, a pharmaceutical giant that emerged from Abbott Laboratories in 2013 and quickly became a leader in immunology, oncology, and aesthetics.From its blockbuster drug Humira to major acquisitions like Pharmacyclics and Allergan, AbbVie has strategically expanded its portfolio and global presence. We’ll break down the company’s history, key milestones, and the vision driving its future—including cutting-edge research in neuroscience and gene therapy.Join me as we...
2025-03-2615 min
BioSpaceTariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, MoreDonald Trump’s tariffs have headlined myriad news stories this week—including at BioSpace, where we reported Pfizer CEO Albert Bourla’s claim that his company is prepared to reshore manufacturing if the president makes good on threats made last month. Eli Lilly also appears to be preparing, commiting $27 billion to boost its U.S. manufacturing capacity. Meanwhile, another regulatory meeting has been canceled under new HHS Secretary Robert F. Kennedy Jr. Reuters revealed last week that an upcoming meeting of the FDA’s external advisers for vaccine policy on March 13 has been canceled—just a week after the CDC...
2025-03-0515 min
BioCentury This WeekEp. 282 - CRISPR Lessons: Plus, AbbVie Enters ObesityThe track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the lessons learned by this small group of companies since their launch a decade ago. They also discuss the entrance of AbbVie into the obesity race via a $350 million deal with Gubra for a clinical stage amylin agonist — does it signal AbbVie’s belief in amylin monotherapy, or will the company be hunting for more o...
2025-03-0423 min
The BeatHLTH: Redefining Clinical Trials: Sasha Tyndale on Inclusive Research at AbbVieAbout Sasha Tyndale:Sasha Tyndale is a seasoned leader in the pharmaceutical industry with over 20 years of experience spanning oncology, immunology, neuroscience, and more. As Director of Diversity and Patient Inclusion at AbbVie, she drives patient-centric strategies and innovative clinical operations. With expertise in precision medicine and personalized healthcare, she collaborates cross-functionally to enhance patient engagement and future-proof organizations. Previously, she held key roles at PAREXEL and Johnson & Johnson, specializing in strategic patient recruitment and clinical innovation. Sasha holds a Master’s and Bachelor’s degree in English Literature from Rutgers University. Passionate about advancing equitable healthcare, she...
2025-02-2016 minThe BeatHLTH: Redefining Clinical Trials: Sasha Tyndale on Inclusive Research at AbbVieAbout Sasha Tyndale:Sasha Tyndale is a seasoned leader in the pharmaceutical industry with over 20 years of experience spanning oncology, immunology, neuroscience, and more. As Director of Diversity and Patient Inclusion at AbbVie, she drives patient-centric strategies and innovative clinical operations. With expertise in precision medicine and personalized healthcare, she collaborates cross-functionally to enhance patient engagement and future-proof organizations. Previously, she held key roles at PAREXEL and Johnson & Johnson, specializing in strategic patient recruitment and clinical innovation. Sasha holds a Master’s and Bachelor’s degree in English Literature from Rutgers University. Passionate about advancing equitable healthcare, she...
2025-02-2016 min
VOCES AbbVieNacho Andrés: la importancia del feedbackDe la mano de Nacho Andrés, responsable de Allergan Medical Institute, profundizamos en la importancia del feedback, por qué nos da miedo pedirlo, qué ocurre si no lo interiorizamos y cómo convertirlo en una oportunidad. ¡Arrancamos Juntos desarrollamos talento, un espacio donde la inspiración y las experiencias de personas que trabajan en AbbVie nos acercan a la gestión y al desarrollo de talento!
2025-02-1315 minVOCES AbbVieNacho Andrés: la importancia del feedbackDe la mano de Nacho Andrés, responsable de Allergan Medical Institute, profundizamos en la importancia del feedback, por qué nos da miedo pedirlo, qué ocurre si no lo interiorizamos y cómo convertirlo en una oportunidad. ¡Arrancamos Juntos desarrollamos talento, un espacio donde la inspiración y las experiencias de personas que trabajan en AbbVie nos acercan a la gestión y al desarrollo de talento!
2025-02-1315 min
Oído ClínicoNudelman (AbbVie) : "España juega un papel protagónico en ensayos clínicos, se hacen muy bien"El ensayo clínico es fundamental para el desarrollo de medicamentos. Es un proceso durante el cual se prueba su seguridad y eficacia antes de salir al mercado. Y España tiene un rol clave en ellos. Por ello, en el último episodio de Oído Clínico, vamos a diseccionar estos procesos fundamentales para la I+D farmacéutica en un episodio especial en colaboración con AbbVie.Para ello, charlamos con Luis Enrique Nudelman, director médico de AbbVie en España, quien admite que el ensayo clínico es un proceso "complejo pero absolutamente crítico para d...
2025-02-0720 min
Talent Acquisition Leaders Podcast - Recruiting, Staffing, Human ResourcesTurning TA Into a Strategic Asset with Assil Omar of AbbVieHost Ryan Dull is joined by Assil Omar, Chief Equity Officer and Vice President, Talent Acquisition of AbbVie. They discuss her unique career journey, the transformation of TA at AbbVie and how the balance between human capital and technology is driving their success.Key Takeaways:(02:40) Assil Omar’s background and entry into TA at AbbVie.(08:21) AbbVie’s organizational structure and TA function.(12:45) The impact of AbbVie’s acquisition of Allergan during COVID.(14:09) Establishing a transformation office to revamp TA.(20:46) Implementing a new op...
2025-01-0728 minC éliminéDr Carine Chagneau : et toi, tu dépistes comment en libéral ?En 9 ans de pratique libérale à Bordeaux, le Dr Carine Chagneau a vu plus d’hépatites C qu’en 20 ans au CHU de Poitiers.Son expérience démontre le rôle des hépato-gastro-entérologues libéraux pour traiter des populations qui ne sont dépistées ni à l’hôpital ni dans les structures d’accueil des populations à risque.En appui des médecins généralistes, et en complément de l’hôpital, elle contribue à sa manière à l’élimination de l’hépatite C d’ici 2030.C éliminé est un podcast sur l’hépa...
2025-01-0708 min
Quarterly BriefingS01-Pharm-E01: AbbVie 3Q 2024In this episode of The Quarterly Briefing, we dive deep into AbbVie's financial performance for Q3 2024, analyzing key strategies in immunology, oncology, and neuroscience. We explore the impact of Humira's decline, the promising future of Skyrisi and Rynvok, advancements in oncology with Imbruvica and Venclexta, and innovations in neuroscience with Graylar and new Parkinson's treatments. Discover how AbbVie's strategic acquisitions and use of digital technologies like AI are shaping their future, ensuring robust growth despite economic uncertainties. Join us for an informative and engaging look into one of the leading pharmaceutical companies.00:00 Introduction to The Quarterly Briefing
2024-12-3018 min
The Readout Loud331: AbbVie’s stumble, Amgen’s tumble and more election falloutWhy are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard? We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about AbbVie’s M&A miscue following the failure of a closely followed schizophrenia drug. You’d hate us if obesity drugs weren’t mentioned, so we oblige with a tick-tock on what went...
2024-11-1430 min
BioSpaceAbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, MorePossibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage trials. Acquired by AbbVie in its $8.7 billion Cerevel Therapeutics buy, this result is in stark contrast to that of Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics, which yielded Cobenfy—the first novel schizophrenia drug approved in 35 years.
Also having a tough month is AstraZeneca, which despite reporting strong Q3 sales Tuesday has been dealing with drama at its China headquarters as a top executive there is being investigated for alleged medical insurance fraud.
Meanwhile, Bayer had le...
2024-11-1315 minC éliminéÉpisode spécial Congrès de l'AFEF 2024 : et toi tu élimines comment l’hépatite C ?Dans cet épisode enregistré pendant les 95èmes journées de l'AFEF, les médecins à qui nous avons tendu notre micro partagent leur expérience sur le terrain et les défis qu’ils rencontrent pour atteindre l’objectif d’élimination de l’hépatite C d’ici 2030 (*).Ils abordent les obstacles majeurs, notamment le dépistage des populations précaires et la réticence de certains patients à se faire traiter. Comment atteindre ces personnes qui restent souvent sous le radar ? Quelles stratégies mettre en place pour renforcer le dépistage et l'accompagnement ?Découvrez leu...
2024-11-0708 min
Future of HR “Raising the Bar on Talent and Culture” with Tim Richmond, EVP & Chief Human Resources Officer, AbbVieHow do you make your company a great place to work year after year?Why is investing in and developing people leaders essential to building a great culture?My guests on this episode is Tim Richmond, EVP & Chief Human Resources Officer, AbbVieDuring our conversation Tim and I discuss: Why creating a strong organizational culture starts with the goal of being known as a great place to workHow AbbVie's innovative "Ways We Work" framework equally weights and rewards both performance and behavioral metricsHis advice to HR leaders on...
2024-10-2953 min
ITAPA podcastAko rozbehnúť inovácie v zdravotníctve na Slovensku? Spoluprácou, tvrdí Antonio Della Croce z AbbVie (ITAPA podcast)Antonio Della Croce, generálny manažér spoločnosti AbbVie pre Českú republiku a Slovensko, diskutoval v podcaste ITAPA o potenciáli inovácií v zdravotnej starostlivosti na Slovensku, pričom zdôraznil dôležitosť zjednotenia európskych systémov s cieľom zrýchliť prístup k inovatívnej liečbe. Vyzdvihol účasť Slovenska na klinických skúškach, no zároveň upozornil na byrokratické a finančné výzvy, ktoré bránia rýchlejšiemu prístupu k novým liekom.
Pandémia COVID-19 bola vnímaná ako katalyzátor spolupráce, ktorý ukázal potenciál pre zrýchlenie procesov. Della Cr...
2024-10-2807 min
Stock QuickdiveAbbVie: Navigating Humira's DeclineAbbVie Inc., a global biopharmaceutical company, is strategizing to maintain growth in a post-Humira era. The company holds leading positions in immunology, oncology, aesthetics, neuroscience, and eye care, with operations in over 70 countries. While its key product, Humira, faces increasing competition from biosimilars after losing exclusivity in 2023, the company is focused on growing newer immunology products, Skyrizi and Rinvoq. Additionally, AbbVie is expanding its portfolio through acquisitions, such as the recent purchase of Cerevel Therapeutics, and strategic collaborations.
Despite revenue decline due to Humira, the company reported strong sales for its newer products and remains committed to research and development...
2024-10-2311 min
Outcomes RocketOperationalizing Cyber with Next-Gen Security Operations with Peter Naumovski, the Global CISO and VP of IT Risk Management at AbbVie, and Teresa Tonthat, Vice President and Associate Chief Information Officer at Texas Children's HospitalEveryone, from top leadership to the frontline, has a role in safeguarding against cyber threats.In this episode, Peter Naumovski, the Global CISO and VP of IT Risk Management at AbbVie, and Teresa Tonthat, Vice President and Associate Chief Information Officer at Texas Children's Hospital, emphasize the critical role of maintaining good cyber hygiene. Peter explains how simple measures like enabling multi-factor authentication, effective vulnerability management, and promptly addressing identified risks can prevent many potential breaches. Teresa discusses the persistent cyber threats targeting the healthcare industry and shares insights into Texas Children’s robust risk evaluation process and...
2024-10-1622 min
Community CornerAbbVie Inc. Behavior - Episode #481Welcome back to the Community Corner podcast! Today we're exploring the behavioral finance logic of AbbVie Inc.! Don't forget to subscribe and leave a like to stay tuned for future episodes! Follow us on Instagram - @communitycorner_podcast Timecodes: 0:15 - Introduction 2:15 - Early Breakthroughs 4:01 - AbbVie Inc.'s Role in the Future
2024-10-0908 minC éliminéJuliette Pont (SOS Hépatites) : et toi, tu dépistes comment l’hépatite C ?Dans cet épisode nous mettons un coup de projecteur sur les actions de l’association SOS Hépatites & Maladies du foie Bourgogne Franche-Comté pour éliminer l’hépatite C. Chaque année depuis 2019, les équipes de l'association vont à la rencontre des populations à risque à travers la région afin d'effectuer des actions de dépistage.Quel est le succès d’une campagne de dépistage ? Comment créer la confiance avec les populations ? Pour le savoir nous avons suivi l’équipe de SOS Hépatites & Maladies du foie Bourgogne Franche-Comté pendant l’un...
2024-09-0311 min
PeDRA PearlsPeDRA's Conversations with Collaborators - Dr. Chudy Nduaka, AbbVieWe're thrilled to kick off our inaugural episode with Dr. Chudy Nduaka, the Therapeutic Area Head of Dermatology at AbbVie's U.S. Medical Affairs. Dr. Nduaka's journey into medicine was inspired by his childhood in Nigeria, driving his passion to develop therapies for those in need. Tune in to hear about his remarkable work and discover the exciting opportunities for PeDRA investigators to collaborate with AbbVie.
2024-08-2610 min
FORECAST#10: Miroslava Stodolicová, Director Future Finance Fit, AbbVie☝️ CHANGE MANAGEMENT.Miroslava Stodolicová z AbbVie říká, že právě toto je ta největší výzva při digitální transformaci CFO agendy ve společnostech.Mirka se ve financích pohybuje přes 20 let a pracovala pro věhlasné mezinárodní společnosti na různých manažerských pozicích. V AbbVie aktuálně zastává pozici ředitele pro digitální transformaci finančního řízení a má plné ruce práce s nasazením sofistikovaného řešení v celé skupině.Je to již druhý pokus modernizovat plánování, forecasting a reporting v AbbVie. Ten první bohužel nedopadl úplně úspěš...
2024-07-1740 minC éliminéFrédéric Chaffraix : et toi, tu dépistes comment hors-les-murs ?Dépister, c’est un bon début, mais sans prise en charge des malades, l’effort est vain. Alors à Strasbourg, au service expert de lutte contre les hépatites virales d’Alsace (SELHVA), Frédéric Chaffraix et son équipe ont co-construit des parcours de soin avec leurs partenaires sur tout le territoire. Quel que soit le lieu où l’équipe mobile se rend pour un dépistage, les liens avec les professionnels de santé locaux leur permettent d’assurer une suite positive à leurs actions. Pour que même hors-les-murs, lorsque les dépistages ont lieu à 150...
2024-06-0407 minC éliminéPr Dominique Thabut : et toi, tu expliques comment à l’hôpital ?Si l’hépatite C continue de faire des victimes, c’est en partie par manque d’information sur les risques de transmission, mais aussi parce que son évolution est majoritairement asymptomatique jusqu’aux stades tardifs de la maladie.Sensibiliser au dépistage, rappeler l’existence des traitements, et expliquer les modes de transmission et de re-contamination fait partie du quotidien des hépatologues comme le Pr Thabut, cheffe de service à la Pitié-Salpêtrière, qui nous reçoit dans son bureau.C éliminé est un podcast sur l’hépatite C proposé...
2024-04-0408 minC éliminéDr Flavie Oster : et toi, tu dépistes comment en CSAPA ?À Strasbourg, le Dr Oster et l’équipe de l’association Ithaque mettent un point d’honneur à donner du temps à celles et ceux qui poussent la porte du CSAPA. Du temps d’accueil, du temps d’écoute, et du temps pour envisager sereinement le dépistage de l’hépatite C.Mais donner du temps n’empêche pas de réagir vite lorsque la possibilité du dépistage se présente. Au contraire, au CSAPA de Strasbourg tout a été mis en place pour saisir l’opportunité de dépister. C éliminé est un podcast sur l’hé...
2024-03-0507 min
Aktien fürs LebenAbbott Laboratories und Abbvie wollen den Kreis zwischen Ernährung, Gesundheit und Schönheit schließenHeute bei Aktien fürs Leben:Wochenrückblick: Die enttäuschende Zahlen von L'Oréal und die Gewerbeimmobilienkrise in den USA (02:38)/Wahre Größe: Warum das Kfz-Ersatzteilgeschäft von Autozone boomt (12:20)/The Trend is your friend: Das clevere Geschäft von Abbott Laboratories und Abbvie (20:10)/Deal or no Deal: Warum DHL keine Aktie fürs Leben ist (28:38)//Um folgende Aktien geht es: L'Oréal (WKN: 853888), Autozone (881531), Abbott Laboratories (850103), Abbvie (A1J84E), DHL (555200) und UPS (929198) //Keine Anlageberatung oder -empfehlung. Alle Angaben ohne Gewähr, diese stellen keinen Ersatz für eine professionelle und individuelle Beratung dar. Wertent...
2024-02-1433 minC éliminéSamuel Besnard : et toi, tu dépistes comment en CSAPA ?À Rennes, deux CSAPA prennent en charge les personnes en situation d’addiction. Samuel Besnard est infirmier, il reçoit tous les patients du CSAPA L’envol pour leur proposer un dépistage dès leur arrivée au centre. Mais sa mission de réduction des risques s’inscrit dans la durée puisqu’il est amené à revoir certains patients à plusieurs reprises en raison des réinfections. C éliminé est une chaine de podcasts sur l’hépatite C proposée par Abbvie en collaboration avec Sons & Merveilles. .Cet épisode a été mixé par Alice Krief...
2024-02-0606 min
Global ValueIs AbbVie Stock a Buy Now!? | ABBV Stock Analysis!In this video, we'll perform an ABBV stock analysis and figure out what AbbVie looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for AbbVie. And answer is AbbVie one of the best stocks to buy at the current price? Find out in the video above! Global Value's AbbVie stock analysis.
Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos!
- 🚨 Join NOW for 7 days of FREE ACCESS to our EXCLUSIVE Investing Tools https://www.patreon...
2024-02-0215 minC éliminéCorinne Rotrou : et toi, tu dépistes comment en CAARUD ?Corinne est infirmière. Elle est rattachée au CHU de Montpellier mais pour réaliser les dépistages elle passe la majorité de son temps en déplacement, à cheval sur plusieurs départements, à la rencontre de tous types de populations. Comme elle le dit elle-même, Corinne pratique un dépistage sur mesure. Un peu comme de la haute couture finalement.C éliminé est un podcast sur le dépistage de l’hépatite C proposé par Abbvie en collaboration avec Sons & Merveilles.Il est réalisé par Alice Krief.[FR-VHCV-230150...
2023-12-1908 min
Dividend TalkEP #174 | Inspirational quotes by Charlie Munger and what we learned from it | & AbbVie's acquisition and Pfizer's withdrawal of weight-loss drugWelcome to Episode 174 of the Dividend Talk Podcast! In this episode, titled "The Best of Charlie Munger Quotes," your hosts EMF and European DGI explore the timeless wisdom of Charlie Munger. They delve into Munger's insightful quotes, discussing their relevance to dividend investing and wealth-building strategies and what it personally meant to them.
In the news segment, EMF shares his thoughts on AbbVie's $10.1 billion deal to acquire ImmunoGen, including the cancer drug ELAHERE. The acquisition is set to strengthen AbbVie's position in treating ovarian cancer and solid tumors, with the deal expected to finalize...
2023-12-021h 11
VOCES AbbVieEnfermedad de Crohn, ¿cómo impacta en la vida de las personas?Bienvenidos a Voces en Enfermedad Inflamatoria Intestinal, un podcast de AbbVie España, en el que ponemos voz a la ciencia. La voz es una herramienta muy poderosa a la hora de comunicar y cuando hablamos de la salud es fundamental escuchar a los pacientes, familiares, a los sanitarios, a quienes trabajan en la investigación. Por eso, queremos alzar la voz a través de este podcast para seguir mejorando el conocimiento de la realidad que viven miles de personas en torno a las enfermedades inflamatorias intestinales.
En este capítulo damos voz a aquellos que conv...
2023-11-2814 minVOCES AbbVieEnfermedad de Crohn, ¿cómo impacta en la vida de las personas?Bienvenidos a Voces en Enfermedad Inflamatoria Intestinal, un podcast de AbbVie España, en el que ponemos voz a la ciencia. La voz es una herramienta muy poderosa a la hora de comunicar y cuando hablamos de la salud es fundamental escuchar a los pacientes, familiares, a los sanitarios, a quienes trabajan en la investigación. Por eso, queremos alzar la voz a través de este podcast para seguir mejorando el conocimiento de la realidad que viven miles de personas en torno a las enfermedades inflamatorias intestinales.
En este capítulo damos voz a aquellos que conv...
2023-11-2814 min
HR Visionaries DeutschlandAbbvie | Guter Tipp zu einer BewerbungIn dieser Folge haben wir mit Kevin von Abbvie geredet. Er hat in einigen internationalen Unternehmen schon gearbeitet und weiß daher viele Sachen über die Bewerbungsprozesse, die ihr sicher braucht, um in einen Unternehmen erfolgreich einzusteigen.
Mehr zu Kevin und Abbvie:
https://www.linkedin.com/in/kevin-strack-034001162/
https://linkedin.com/company/abbvie/
https://www.abbvie.com/058531
hyrd:
https://www.instagram.com/gethyrd/
https://www.linkedin.com/company/gethyrd/
https://www.facebook.com/gethyrd/
https://twitter.com/gethyrd
get hyrd Podcast:
https://open.spotify.co...
2023-08-0946 minGlobal ValueIs AbbVie Stock a Buy Now!? | AbbVie (ABBV) Stock Analysis! |In this video, we'll perform an ABBV stock analysis and figure out what AbbVie looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for AbbVie. And answer is AbbVie one of the best stocks to buy at the current price? Find out in the video above! Global Value's AbbVie stock analysis.
TIKR is the website I use for all financial data in my videos. Join me and thousands of investors worldwide by using TIKR to supercharge your investment analysis. All funds from referrals directly support the channel to improve...
2023-08-0611 min
Eyes onUOS, Global Research Pharmaceutical Company AbbVie sign MOUWith the aim of promoting and strengthening sustainable cooperation, the University of Sharjah signed a memorandum of understanding with the global, research, pharmaceutical company "AbbVie”, signed on behalf of the University of Sharjah by its Chancellor, His Excellency Prof. Hamid M.K. Al Naimiy, and on behalf of the company, His Excellency Hassan Sabbah, General Manager of AbbVie in the Gulf and Levent region.
The agreement aims to enhance students' cognitive skills in various aspects of the pharmaceutical industry, including talent management, promoting research, development and knowledge exchange in the field of biopharmaceuticals, creating a pool of future talent for ph...
2023-07-2603 min
Eyes onUOS, Global Research Pharmaceutical Company AbbVie sign MOUWith the aim of promoting and strengthening sustainable cooperation, the University of Sharjah signed a memorandum of understanding with the global, research, pharmaceutical company "AbbVie”, signed on behalf of the University of Sharjah by its Chancellor, His Excellency Prof. Hamid M.K. Al Naimiy, and on behalf of the company, His Excellency Hassan Sabbah, General Manager of AbbVie in the Gulf and Levent region.
The agreement aims to enhance students' cognitive skills in various aspects of the pharmaceutical industry, including talent management, promoting research, development and knowledge exchange in the field of biopharmaceuticals, creating a pool of future talent for ph...
2023-07-2603 min
Global ValueAbbvie Stock Analysis | ABBV Stock | $ABBV Stock Analysis | Best Dividend Stock to Buy Now?In this video, we'll perform an ABBV stock analysis and figure out what the company looks like based on the numbers. Is Abbvie Inc one of the best Dividend stocks to buy at the current price? Find out in the video above! Global Value's Abbvie Inc stock analysis.
Check out Seeking Alpha Premium and score an annual plan for just $119 - that's 50% off! Plus all funds from affiliate referrals go directly towards supporting the channel!
Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/
...
2023-04-1711 min
PrincipledS9E10 | What you say and how you say it: Thoughtful communication at AbbVieThe benefits of civility in the workplace are well documented. Operating through a lens of courtesy, integrity, and respect helps align teams, lift productivity, and reduce risk. But how to create a workplace environment that prizes these things when so much of society has become so... uncivilized? How can we maintain our own composure in this trying environment, and is it important? In this episode of the Principled Podcast, host Jen Uner explores the value of thoughtful communications with Shana Fried and Marie Corchado-Stewart, two key compliance executives at the global pharmaceuticals company AbbVie. Listen in as Shana and Mari...
2023-04-1419 min
The 7investing PodcastMarket Madness Round 1: AbbVie (#2) vs Coinbase (#15)Welcome to our 7investing March Madness competition! Throughout this campaign, we’re matching popular stocks up against one another to determine which will be the best investment over the next three years. And then, by voting in the poll at the bottom of the article, you can help us determine which stock will go on to the next round!
Our rankings are determined by the total return of the stock during calendar 2022. The highest-ranked stock had the best overall return of those in our tournament, and our lowest-ranked stock had the lowest overall return.
In th...
2023-03-1632 min
Best Worst Club- Endometriosis LifeDeep Dive into AbbVie's Orilissa for Endometriosis- Just the Beginning Pt 1Disclaimer- The stories you are about to hear are the personal experiences of each individual and the views expressed by guests are their own. Please listen with discretion as this series contains mature content that could possibly be triggering to some individuals. Mention of depression, suicidal ideation, medical trauma, sexual assault, disorder eating and other sensitive topics may come up. Please listen at your own discretion and remember this podcast is never meant to be taken as medical advice.
Let's take a look at the state of AbbVie before Orilissa hit the market and where the motives...
2023-02-1019 min
The Scope of ThingsEpisode: 10 - Abbvie’s Christopher Boone on Disrupting the Clinical Research EnterpriseA self-described “data hippie,” Christopher Boone, vice president and global head of health economics and outcomes research at AbbVie, knows a great deal about using real-world data and generating real-world evidence in clinical trials. Boone sits with host Deborah Borfitz to talk about the disruptive presence of real-world evidence within the clinical trial enterprise and how it encourages researchers to reimagine trial design from start to finish. He says, “Much of the data we care about is captured outside the walls of the provider environment… Now, with all the digital technology, you can really understand the [patient’s] environment and experi...
2023-01-0327 min
Business Of BiotechOncology Discovery Advances With AbbVie's Steve Davidsen, Ph.D.We love to hear from our listeners. Send us a message. AbbVie VP of Oncology Discovery Research Steve Davidsen, Ph.D. is a living, breathing timeline of the company's cancer research and development efforts. He got his start with the company— Abbott at the time— way back in 1986. As such, he's charted the adoption of multiple advanced technologies that have contributed to the realization of dozens of molecular weapons in the fight against cancer. On this episode of the Business of Biotech, Dr. Davidsen shares the latest on AbbVie's adoption of computational biology and how it's contributing to disc...
2022-10-1040 min
Stock StoriesAbbVie And Pharmaceutical Industry BasicsSome businesses rise on their own as the result of a spin-off from a larger business. AbbVie is one of these! In today’s episode we learn about what AbbVie has going for it as well as some of the risks investors should consider.0:00 - Start1:18 - How Did AbbVie Get Started?2:10 - Tax Inversions3:50 - How The Business Works8:08 - Financials14:35 - Final Thoughts On AbbVie👀 Subscribe on YouTube:https://youtube.com/channel/UCKwdV2I2k0tWvjVpa...
2022-04-1316 min
What is UX?S5E9 An Interview with Pawel Bak, Lead Product Designer, Manager at AbbViePawel Bak is a strategic and passionate product/service designer with 12+ years of experience designing for mobile, wearables and IoT devices. Designs and helps develop high-performing design solutions and engaging customer experiences which drive business goals and user satisfaction for well-known brands. An innovative and hard-working leader who is both strong on ideation and implementation, as well as on enabling global agile teams to succeed. Mentors designers and manages established or growing design teams. Builds collaborations and establishes trust to engage and influence global stakeholders.In this episode, we talked about:
2022-04-1329 min
OIS Podcast | Ophthalmology's leading PodcastLessons Learned by AbbVie’s StewartWhen Andrew Stewart moved into his current role of global eye care general manager at AbbVie, his top two priorities were to help continue to grow Ozurdex® and to help get the company ready for the launch of Abicipar.The phrase about “the best-laid plans…” proved true, as the FDA declined to approve the company’s Biologics License Application (BLA) for abicipar due to higher than acceptable rates in intraocular inflammation. “It was an economic decision and a patient decision to stop moving forward with the product,” Andrew told host Firas Rahhal, MD, a retina specialist and partner at Re...
2022-04-0628 min
Xtalks Life Science PodcastPfizer’s COVID-19 Antiviral Pill + FDA Approves AbbVie’s Eyedrop for PresbyopiaIn this episode, the editorial team discussed Pfizer’s new oral antiviral pill for the treatment of COVID-19. Pfizer released data from an interim analysis of a Phase III trial evaluating the drug, which shows that it can reduce the risk of hospitalizations by almost 90 percent. It also prevented COVID-19 related deaths in the study. The results were so strong that an independent data monitoring committee and the FDA told Pfizer they could stop enrolling participants in the trial. Ayesha and the team discussed the convenience of an oral medication for COVID-19, and how such drugs appear to be mo...
2021-11-1032 min
Collect CashIs AbbVie's High Dividend Safe? ABBV Stock AnalysisAbbvie ABBV Stock continues to remain a favorite of dividend investors because of it's high dividend yield as well as chances for some amazing capital appreciation. In today's video I go over Abbvie Pharmaceutical's business model and if their products will be in demand even after their patents expire. Abbvie's strong cash flow from its diversified product line continue to be able to fund it's high dividend yield. Abbvie has an impressive 5 year dividend growth rate of nearly 17% and has seen its share price rise considerably in the past 5 years. I also talk about some of their next in...
2021-10-2307 min
Personal JurisdictionLet's Get Personal with Amy Chapple, U.S. Commercial Brand Counsel at AbbViePlease note that the content in this podcast reflects Amy Chapple's opinions only and not the opinions of AbbVie. Amy Chapple is U.S. Commercial Brand Counsel at AbbVie in Deerfield, Illinois. She is a 2014 graduate of University of Illinois Chicago School of Law and a 2007 graduate of Loyola University of Chicago. We tried some new things in this episode with Amy. Let us know what you think! We'd LOVE to hear from you. Email us at personaljxpod@gmail.com or tweet at us @personaljxpod Our Theme Song is Pleasant Porridge by Kevin Mac...
2021-10-191h 09
Dr Robert Hess - Ready for the battle?Dr Robert Hess: New relief for Migraine sufferers as FDA approves AbbVie’s QULIPTA (Atogepant)Towards the end of September, Chicago-based biotechnology pharmaceutical giant AbbVie announced that the FDA had approved its QULIPTA (Atogepant) medication for the preventive treatment of episodic migraine in adults. The FDA has thus given the green light to the first and so far only oral CGRP (calcitonin gene-related peptide) receptor antagonist specifically formulated for the preventive treatment of migraine.
Peter J. Goadsby, professor at the University of California, Los Angeles, and at King’s College London, described the FDA approval of QULIPTA as a milestone in the treatment of migraine. Goadsby, who was awarded the prestigious Brain Prize in 2021 for hi...
2021-10-1804 min
The Bottom EndDating and IBDDating is tricky enough at the best of times, but throw in living with IBD and things can sometimes get complicated! How do you tell someone about your condition? When do you tell them? Will it affect how they feel about you? Justan, Brittani and Luke consider all these questions and reveal some of their own dating experiences.Please note: this episode includes discussions of an adult nature and may not be suitable for younger listeners.The Bottom End Podcast Series is an initiative owned by AbbVie Pty Ltd...
2021-09-1625 min
The Bottom EndLife, school and social mediaDealing with school, exams and eventually moving out to live on your own are all a big deal for anyone. But how does living with IBD at the same time affect all that? Luke, Brittani and Justan take us through what happened at these points in their own lives and talk about how they managed it.The Bottom End Podcast Series is an initiative owned by AbbVie Pty Ltd, and created with the support of Crohn’s and Colitis Australia. Information is intended for Australian residents only and is not intended to replace the ad...
2021-09-1630 min
The Bottom EndThe Bottom End returns in 2021 with two new episodesThe Bottom End Podcast Series is an initiative owned by AbbVie Pty Ltd, and created with the support of Crohn’s and Colitis Australia. Information is intended for Australian residents only and is not intended to replace the advice of your healthcare professional.For further information about your medical condition, please talk to your healthcare professional. AbbVie® is a registered trademark of AbbVie Inc. ©2021 AbbVie Pty Ltd. ABN 48 156 384 262, Mascot, NSW 2020. www.abbvie.com.au AU-IMMG-210019. July 2021.
2021-09-1601 min
State Of ReadinessDavid Mackey; Senior Manager, AbbVie Video Version https://vimeo.com/567169449 About the Podcast I invite David Mackey is a senior manager at AbbVie presently responsible for the implementation of the SAP "procure to pay" processes at AbbVie. Previously, he was the Director of Operational Excellence at Pharmacyclics (a subsidiary of AbbVie). In addition to AbbVie, he has had senior leadership roles at Genentech and Roche. We start the conversation with David's early days when he was "...
2021-08-091h 01
Michael GarzaAbbvie (ABBV) - Stock Market Crash WatchlistAbbvie has been an incredibly strong name in the healthcare sector and should be taken seriously as a growth company. Add these mofos to your portfolio fool!!!
#Abbvie #ABBV #Watchlist #StockMarketCrash
2021-07-2711 min
VOCES AbbVieBienvenido a VOCESVOCES es un podcast de Abbvie que da voz a pacientes y profesionales sanitarios en torno a la salud.
2021-06-2300 minVOCES AbbVieBienvenido a VOCESVOCES es un podcast de Abbvie que da voz a pacientes y profesionales sanitarios en torno a la salud.
2021-06-2300 minXtalks Life Science PodcastClinical Trials Day 2021 + AbbVie’s Humira MonopolyIn this episode, Ayesha talks about Clinical Trials Day 2021 and how the COVID-19 pandemic spurred changes in trial procedures and perceptions of clinical research. At the onset of the pandemic, many clinical trial sites had to be shut down, prompting trial sponsors and practitioners to move to remote, decentralized clinical trial models. Researchers had to adapt quickly to minimize trial disruptions. Xtalks spoke to experts in the field who say decentralized and hybrid trials are here to stay even after the pandemic, as they can improve the patient experience and incorporate modern digital technologies for enhanced data collection and...
2021-05-2633 min
Health Science CoachMedical Sales Management | Jeff Edmundson | AbbVie | Careers in Health Care | Episode 11Welcome to the 11th episode of Health Science Coach, a guide to your health care career. Today we take a look into the life of a Medical Sales Manager at AbbVie Pharmaceutical Research and Development.
Like - Comment - Subscribe
Jeff Edmundson - Senior District Manager-Immunology Patient Outreach at AbbVie
Bachelors of Arts in Psychology and Philosophy from University of Nebraska, Lincoln
Masters of Science in Counseling from University of Nebraska, Omaha
About
Successful, motivated sales professional with extensive experience in sales management and tra...
2021-04-2233 min
Phil with F30"This Dr. has a Planet Named After Him" (Dr. Buchman at AbbVie BioPharmaceutical)Today’s guest on the “Phil with F30” podcast is Dr. Marek Buchman – Research Scientist of AbbVie BioPharmaceuticals
Forbes List: Slovakia
Year: 2018
Category: Science and Education
Dr. Marek Buchman showed his chemistry talents early when he co-authored his first patent at 15. He left his home in Slovakia and studied at the University of Oxford, and to date, he scored the highest in their organic chemistry exams. Dr. Buchman earned his PhD. from the KC Nicolao lab at Rice University, where he co-authored a patent that a pharma company recently licensed.
He currently works as a research scientist and is a postdoctor...
2020-12-2042 min
Monitor MondaysCalifornia Whistleblower Claim Yields $24 Million Abbvie SettlementCalifornia is one of two states in the country that rewards whistleblowers for bringing forward information about private insurance fraud. A recent $24 million settlement with pharmaceutical giant Abbvie over the marketing of the company’s blockbuster drug, Humira, demonstrates the law’s effectiveness.The settlement agreement was reached last week following allegations that the company violated California’s Insurance Frauds Prevention Act. Abbvie agreed to the settlement despite continuing to deny any wrongdoing.On the next live edition of Monitor Mondays, famed whistleblower attorney Mary Inman, partner in the London office of Constantine Cannon, will provid...
2020-08-1730 min
Los podcasts de Dividendo RentableAbbvie, 1 año despuésEn este podcast actualizo el análisis que hice en agosto de 2019 sobre Abbvie.
Índice:
1. INTRODUCCIÓN: EL MENSAJE
2. EL NEGOCIO, EL MOAT Y LOS RIESGOS
3. PORTFOLIO DE FÁRMACOS
4. COLABORACIONES
5. LA OPA A ALLERGAN
6. ALGUNOS NÚMEROS DE LA NUEVA ABBVIE
7. CAPITAL ALLOCATION
8. DIVIDENDOS
9. RECOMPRA DE ACCIONES
10. DIRECTIVA
11. ABBVIE EN 2020 Y PLAN ESTRATÉGICO 2025
12. ¿CÓMO DE BARATA O CARA ESTÁ?
13. CONCLUSIONES
Como siempre, esto NO ES RECOMENDACIÓN DE NADA. Que cada uno haga sus propios análisis.
2020-08-1555 min
Better by Great Place To WorkSummit Series: Season 2: The Ways We Work An Interview With AbbVie CHRO Tim Richmond
Tim Richmond leads AbbVie’s global human resources function, focused on employee engagement and driving business performance through culture. He is a driving force behind AbbVie’s diverse talent pipeline. In this interview, Tim shares how important it is to set clear standards, clear expectations, and give people a north star. Tim delves into the five pillars of what AbbVie call the “Ways We Work.” These pillars engage AbbVie employees, allowing them to put themselves out there, feel trusted, and feel supported, which is all critical to AbbVie’s culture. Learn what differentiates a good company from a great company and how th...
2020-08-1022 min
Frictionless MarketingAbbVie's Head of Communications, Javier Boix on Effective Storytelling in Healthcare Communications“Storytelling is much more a science than an art. But it’s still an art, and it needs to be informed by science, meaning analytics data.”In today's interview, Lippe Taylor CEO Paul Dyer sits down with Javier Boix, the Head of U.S. Communications at AbbVie to dive into the true meaning of the commonly-used term “storytelling” in the context of communications and analytics. They also look at how to approach one's career as a generalist versus a specialist and much more. Here are some key takeaways from this conversation with Javier: Communications pros need to f...
2020-07-0939 min
The Bottom EndIBD and MeThe challenges that IBD can pose to your life and your self-esteem can seem daunting. Brittani, Justan and Luke share how they coped, and they talk about what messages they’d send to their younger selves. Dr. Ed shares some of the positivity and inspiration he sees in his patients.“The Bottom End Podcast Series is an initiative owned by AbbVie Pty Ltd, and created with the support of Crohn’s and Colitis Australia. Information is intended for Australian residents only and is not intended to replace the advice of your healthcare professional. For furthe...
2020-06-2623 min